MyBlueDotsBioSkryb Genomics Launches ResolveSEQ MRD: A Next-Generation Measurable Residual Disease (MRD) Discovery Solution MyBlueDots6 months ago01 mins DURHAM, N.C.–(BUSINESS WIRE)–BioSkryb launches ResolveSEQ MRD, an innovative service offering designed to empower further classification and characterization of MRD cells. Post navigation Previous: Instem Introduces Cloud-Hosted Non-GLP Pathology Module for ProvantisNext: RefleXion Launches Pivotal Study to Expand SCINTIX Therapy and Announces Broader Medicare Reimbursement
Engineers create first immunocompetent leukemia device for CAR T immunotherapy screening MyBlueDots3 days ago 0
Improvements to patient recovery strategies lower long-term opioid usage after colorectal surgery MyBlueDots3 days ago 0